JP2022512904A5 - - Google Patents
Info
- Publication number
- JP2022512904A5 JP2022512904A5 JP2021523954A JP2021523954A JP2022512904A5 JP 2022512904 A5 JP2022512904 A5 JP 2022512904A5 JP 2021523954 A JP2021523954 A JP 2021523954A JP 2021523954 A JP2021523954 A JP 2021523954A JP 2022512904 A5 JP2022512904 A5 JP 2022512904A5
- Authority
- JP
- Japan
- Prior art keywords
- aureus
- antigen
- antibody
- seq
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770608P | 2018-11-21 | 2018-11-21 | |
| US62/770,608 | 2018-11-21 | ||
| US201962822029P | 2019-03-21 | 2019-03-21 | |
| US62/822,029 | 2019-03-21 | ||
| US201962865436P | 2019-06-24 | 2019-06-24 | |
| US62/865,436 | 2019-06-24 | ||
| PCT/US2019/062370 WO2020106814A1 (en) | 2018-11-21 | 2019-11-20 | Anti-staphylococcus antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512904A JP2022512904A (ja) | 2022-02-07 |
| JP2022512904A5 true JP2022512904A5 (https=) | 2022-10-05 |
Family
ID=68848487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523954A Pending JP2022512904A (ja) | 2018-11-21 | 2019-11-20 | 抗Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12024556B2 (https=) |
| EP (1) | EP3883963A1 (https=) |
| JP (1) | JP2022512904A (https=) |
| KR (1) | KR20210093856A (https=) |
| CN (1) | CN112867732A (https=) |
| AU (1) | AU2019384790A1 (https=) |
| BR (1) | BR112021005522A2 (https=) |
| CA (1) | CA3110377A1 (https=) |
| CL (2) | CL2021001307A1 (https=) |
| CO (1) | CO2021003752A2 (https=) |
| IL (1) | IL281056A (https=) |
| MA (1) | MA55134A (https=) |
| MX (1) | MX2021005863A (https=) |
| PH (1) | PH12021550538A1 (https=) |
| SG (1) | SG11202102060PA (https=) |
| WO (1) | WO2020106814A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117106077B (zh) * | 2022-04-28 | 2024-07-16 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| CN118580347B (zh) * | 2024-05-13 | 2025-02-07 | 重庆原伦生物科技有限公司 | 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用 |
| CN120943954B (zh) * | 2025-10-20 | 2026-02-06 | 重庆原伦生物科技有限公司 | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 |
| CN120988116B (zh) * | 2025-10-24 | 2025-12-30 | 重庆原伦生物科技有限公司 | 针对金黄色葡萄球菌IsdB的抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030224000A1 (en) * | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7488807B2 (en) * | 2006-11-22 | 2009-02-10 | 3M Innovative Properties Company | Antibody with protein A selectivity |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2012122533A2 (en) * | 2011-03-10 | 2012-09-13 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal proteins isda or isdb |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2013096948A1 (en) * | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
| PL3366705T3 (pl) | 2012-09-12 | 2023-09-18 | Genzyme Corporation | FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| TWI781130B (zh) * | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| CA3076632A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
-
2019
- 2019-11-20 CA CA3110377A patent/CA3110377A1/en active Pending
- 2019-11-20 US US16/689,593 patent/US12024556B2/en active Active
- 2019-11-20 CN CN201980068132.9A patent/CN112867732A/zh active Pending
- 2019-11-20 BR BR112021005522-3A patent/BR112021005522A2/pt not_active IP Right Cessation
- 2019-11-20 EP EP19818439.2A patent/EP3883963A1/en not_active Withdrawn
- 2019-11-20 KR KR1020217010936A patent/KR20210093856A/ko active Pending
- 2019-11-20 AU AU2019384790A patent/AU2019384790A1/en not_active Abandoned
- 2019-11-20 MA MA055134A patent/MA55134A/fr unknown
- 2019-11-20 WO PCT/US2019/062370 patent/WO2020106814A1/en not_active Ceased
- 2019-11-20 MX MX2021005863A patent/MX2021005863A/es unknown
- 2019-11-20 SG SG11202102060PA patent/SG11202102060PA/en unknown
- 2019-11-20 JP JP2021523954A patent/JP2022512904A/ja active Pending
-
2021
- 2021-02-23 IL IL281056A patent/IL281056A/en unknown
- 2021-03-11 PH PH12021550538A patent/PH12021550538A1/en unknown
- 2021-03-24 CO CONC2021/0003752A patent/CO2021003752A2/es unknown
- 2021-05-19 CL CL2021001307A patent/CL2021001307A1/es unknown
-
2023
- 2023-10-17 CL CL2023003084A patent/CL2023003084A1/es unknown
-
2024
- 2024-05-21 US US18/670,663 patent/US20240301041A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512904A5 (https=) | ||
| RU2698131C2 (ru) | Антитела к поверхностным детерминантам s. aureus | |
| EP3157565B1 (en) | Treatment of polybacterials infections | |
| US5530102A (en) | Methods and compositions for the direct concentrated delivery of passive immunity | |
| JP2021063090A5 (https=) | ||
| KR20210072057A (ko) | 항-황색포도상구균 항체의 조합 | |
| JP2022536469A5 (https=) | ||
| JP2022512904A (ja) | 抗Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ抗体およびその使用 | |
| US20060153857A1 (en) | Method of treating staphylococcus aureus infection | |
| KR20140145587A (ko) | 면역글로불린을 이용한 점막염의 치료 | |
| Akiyama et al. | Antibacterial Properties of Pseudomonas aeruginosa Immunotype 1 Lipopolysaccharide‐Specific Monoclonal Antibody (MAb) in a Murine Thigh Infection Model: Combined Effects of MAb and Ceftazidime | |
| CN117771379B (zh) | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 | |
| RU2808018C2 (ru) | Антитела к поверхностным детерминантам s. aureus | |
| HK1236126B (en) | Treatment of polybacterials infections | |
| HK1236126A1 (en) | Treatment of polybacterials infections | |
| NZ764692B2 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| NZ764692A (en) | Compositions and methods for treating and preventing staphylococcus aureus infections |